Publications by authors named "Yiu-Tung Anthony Wong"
Article Synopsis
- - Subclinical thrombus formation at the aortic valve complex (including valvular and perivalvular) occurs frequently after transcatheter aortic valve replacement (TAVR), affecting about 43% of patients in the study.
- - The study identified small stent diameter and low body surface area as independent predictors of thrombus formation, with decreased renal function linked to leaflet thrombus specifically.
- - Despite the high incidence of thrombus after TAVR, there were no significant changes in neurological outcomes or new cerebral lesions among patients, indicating that the presence of thrombus may not impact clinical outcomes significantly.
Article Synopsis
- The study investigates the risk of leaflet thrombosis and cerebral thromboembolism in patients undergoing transcatheter aortic valve replacement (TAVR), comparing the effects of low-dose and standard-dose edoxaban versus dual antiplatelet therapy (DAPT).
- Results showed that standard-dose edoxaban significantly reduced the incidence of leaflet thrombosis (2.4%) compared to DAPT (18.3%), while low-dose edoxaban had no significant advantage over DAPT (15.0% vs 18.3%).
- Despite the differences in leaflet thrombosis rates, there were no significant changes in new cerebral lesions or neurological dysfunction among the groups.
Article Synopsis
- The study investigated the effects of subclinical leaflet thrombosis (HALT) on bioprosthetic valve function and durability after transcatheter aortic valve replacement (TAVR).
- In a multicenter trial, HALT was assessed using CT scans and echocardiography, and the study found that HALT was present in 14.2% of patients but did not significantly impact valve mean gradients at six months.
- Key predictors for structural valve deterioration (SVD) included older age, smaller valve size, and higher post-TAVR pressure gradient, while HALT was not a predictor of SVD.
It is unknown whether edoxaban versus dual antiplatelet therapy (DAPT) has differential treatment effects on leaflet thrombosis, cerebral thromboembolism, and neurologic or neurocognitive dysfunction according to clinical and anatomic factors after transcatheter aortic valve implantation. To investigate the relative effects of edoxaban and DAPT on leaflet and cerebral thromboembolism in patients with major risk factors. The primary end point of this study was the incidence of leaflet thrombosis on computed tomography at 6 months.
View Article and Find Full Text PDFBackground: It is unknown whether the direct oral anticoagulant edoxaban can reduce leaflet thrombosis and the accompanying cerebral thromboembolic risk after transcatheter aortic valve replacement. In addition, the causal relationship of subclinical leaflet thrombosis with cerebral thromboembolism and neurological or neurocognitive dysfunction remains unclear.
Methods: We conducted a multicenter, open-label randomized trial comparing edoxaban with dual antiplatelet therapy (aspirin plus clopidogrel) in patients who had undergone successful transcatheter aortic valve replacement and did not have an indication for anticoagulation.
Introduction: Current international guidelines recommend non-vitamin K oral anticoagulants (NOACs) for stroke prevention among patients with non-valvular atrial fibrillation (AF) at significant ischaemic stroke risk given the superior safety and comparable efficacy of NOACs over warfarin. Nonetheless, the safety and effectiveness of NOACs have not been evaluated in patients with AF with underlying moderate or severe mitral stenosis (MS), hence the recommended stroke prevention strategy remains warfarin therapy.
Method And Analysis: MS remains disproportionately prevalent in Asian countries compared with the developed countries.
Background: Patients who survive myocardial infarction (MI) are at risk of recurrent cardiovascular (CV) events. This study stratified post-MI patients for risk of recurrent CV events using the Thrombolysis in Myocardial Infarction (TIMI) Risk Score for Secondary Prevention (TRS 2°P).
Methods and results: This was an observational study that applied TRS 2°P to a consecutive cohort of post-MI patients.
Background: This study sought to evaluate the optimal treatment for in-stent restenosis (ISR) of drug-eluting stents (DESs).
Methods: This is a prospective, multicenter, open-label, randomized study comparing the use of drug-eluting balloon (DEB) versus second-generation everolimus-eluting stent for the treatment of DES ISR. The primary end point was in-segment late loss at 9-month routine angiographic follow-up.